EMYRIA LIMITED — Board/Management Information 2021

Jan 31, 2021

01/02/2021

ASX Announcement

Emyria boosts Medical Advisory board with appointment of Naval Veteran and consultant psychiatrist Dr Richard Magtengaard

Highlights:

• Consultant psychiatrist and retired Naval Officer Dr Richard Magtengaard to join Emyria’s Medical Advisory Board

• Dr Magtengaard is the current Director of Military Trauma Recovery Programme for sustained physical and psychological traumas

• Appointment boosts Emyria’s clinical expertise in mental health care

• Appointment to support Emyria’s mental health-focussed drug development programs, clinical studies and new evidenced-based clinical service models

Emyria Limited (ASX: EMD) (Emyria or the Company), a data-backed drug development company, is pleased to announce the appointment of Consultant Psychiatrist Dr Richard Magtengaard, to its Medical Advisory Board.

The appointment will support Emyria’s multiple mental health focussed initiatives targeting unmet needs in mental health. This includes an initial drug development program - EMD-003 - targeting psychological distress and the symptoms of anxiety, depression and stress (see ASX release 25 NOV 20) as well as the development of an evidenced-based psychedelic-assisted therapy program for patients with major mental health concerns partnership with Mind Medicine Australia to (see ASX release 19 NOV 20).

Dr Magtengaard is a Consultant Psychiatrist with nearly 20 years of clinical and administrative experience and also served for 10 years as a Commissioned Officer within the Royal Australian Navy, before retiring to complete his Medical Degree.

Dr Magtengaard is currently the Director of the Military Trauma Recovery Programme across 2 busy sites of care, namely Marian Centre Hospital (a 69 bed Tier 1 DVA Accredited private hospital) and Salvado (an interdisciplinary setting for specialist care). This programme remains dedicated to assisting Defence Personnel, Veterans and other First Responder Organisations and their families, who have sustained physical and psychological traumas during the performance of their duties.

1

==> picture [137 x 40] intentionally omitted <==

Richard is Chair of the Medical Advisory Committee at Marian Centre Hospital and a member of St John Ambulance Expert Advisory Group. He remains an active member of the Australasian Military Medical Association (AMMA) and has developed lasting affiliations with ADF Joint Health Command (JHC), Returned Services League WA (RSLWA), St John Ambulance (SJA), West Australian Police (WAPOL), Department of Fire and Emergency Services (DFES), Australian Federal Police (AFP) and numerous other Ex-Service Organisations (ESOs).

==> picture [173 x 172] intentionally omitted <==

Richard is also a Foundation member of Oqea and is refining this innovative platform to improve the well-being of participants, with meaningful support and collaboration for the hard-working clinician, busy administrators, alongside meeting the needs of funding bodies.

Emyria’s Managing Director, Dr Michael Winlo , said: “We’re delighted to add Dr Magtengaard to our esteemed Medical Advisory Board. Dr Magtengaard is a highly respected psychiatrist with expertise in mood disorders, chronic pain and PTSD. Dr Magtengaard has a particular passion for improving care for Australian military veterans and for using technology and innovation to improve care delivery.

Dr Magtengaard’s appointment boosts Emyria’s expertise in mental health as we progress our own drug development, care model design and clinical research into the growing global health concern of mental health.”

Dr Richard Magtengaard , said: “I’m passionate about improving mental health, particularly for those who serve. Tackling the growing challenge of mental health will require new technologies, treatments and data-backed ways of caring for patients. Emyria is leading some great initiatives in these areas which is why I’m excited to support their mission.”

Emyria’s first end-to-end drug development program - EMD-003 (see ASX announcements 25 Nov 20 and 05 Jan 21) is a cannabinoid-based medicine seeking registration as a Schedule 3 medicine with the Therapeutic Goods Administration’s (TGA) Australian Register of Therapeutic Goods (ARTG). The regulations allowing the registration of low-dose CBD (<150mg) as a Schedule 3 medicine come into effect on Feb 1st, 2021. Successful registration will require substantial evidence of quality, safety and effectiveness. The development of EMD-003 is informed by Emyria’s Real-World Evidence (RWE) and backed by unique intellectual property (IP). EMD-003 will target psychological distress and the symptoms and anxiety, depression and stress.

This announcement has been approved and authorised for release by the Managing Director of Emyria Limited.

2

==> picture [137 x 40] intentionally omitted <==

For further information:

Dr Michael Winlo Lexi O’Halloran Managing Director Media/Investor Relations (08) 6559 2800 + 61 (0) 404 577 076 mwinlo@emyria.com lexi@janemorganmanagement.com.au

Andrew Williams Media Relations +61 (0) 412 614 125 andreww@proflemedia.com.au

About Emyria (www.emyria.com)

Emyria Limited is a data-backed, drug development company. Emyria’s Treatments target unmet needs and are focused on obtaining approval from major global regulators. Emyria’s drug development programs are informed by insights generated from extensive analysis of Emyria Data - deep, ethically-sourced clinical evidence that is gathered with patients across Emyria’s independent clinical services ( Emerald Clinics - www.emeraldclinics.com.au)

Emyria Data provides deep treatment insights and is therefore a source of unique IP, strategically designed drug development and personalised care programs.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

3